Eli Lilly's investigational once-weekly shot retatrutide cut breathing interruptions in moderate-to-severe obstructive sleep apnea across two phase 3 trials published in the New England Journal of Medicine, EMJ and Physician's Weekly reported. The drug hits GIP, GLP-1, and glucagon receptors. It is not FDA-approved.

In TRIUMPH-1-OSA, the 9 mg dose cut apnea-hypopnea index events by 34.3 per hour versus 9.9 with placebo. In TRIUMPH-2-OSA among people with type 2 diabetes, 9 mg and 12 mg cuts were 24.7 and 25.4 events per hour versus 10.3 with placebo. Trials ran 80 weeks in adults with BMI of at least 27. Across both studies about 691 people were randomized.

Weight loss ran with the breathing gains. TRIUMPH-1-OSA participants on retatrutide lost about 12.5 to 22.2 percent of body weight versus 4.8 percent on placebo, EMJ reported. Bootleg "reta" harms covered earlier this month are separate from these controlled trials.

Physician's Weekly said baseline apnea burden was high, with mean index values above 55 events per hour in both study groups. Authors cast the results as a possible future option for adults with apnea and excess weight, pending regulators.

Sleep apnea raises heart and crash risks when left untreated. CPAP remains the main device therapy, but many patients struggle to stick with masks. A weekly shot that also cuts weight would open a new path if approved later.

Trial patients got weekly shots for many months. Breath pauses fell as weight fell too. Regulators have not cleared the drug for sale.

What we know: Phase 3 NEJM data show large apnea-index drops with retatrutide. The drug is not approved.
What we don't: FDA timing, labeling, and how results compare with other obesity medicines for apnea.